CIRM Funded Clinical Trials
Evaluation of Safety and Preliminary Efficacy of Escalating Doses of GRNOPC1 in Subacute Spinal Cord Injury
Geron carried out a Phase 1 clinical trial to assess the safety and preliminary activity of escalating doses of human embryonic stem cell (hESC) derived oligodendrocyte progenitor cells for treatment of spinal cord injury. Five patients were treated, all safely and without any serious side effects, before the trial was halted by Geron for financial reasons. The work in this trial later has since been revived by Asterias Biotherapeutics, which is conducting a Phase 1/2 clinical trial that CIRM is funding.